GGrantIndex
← Leaderboards

Biomedical Research Models, Inc.

Worcester, MA

Compare ↔
$14,254,218
Total funding
16
Grants

Funding over time

peak $2.3M · FY2005–17
$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17

Funding mix

By agency

NIH$14,254,218 · 16

By mechanism

R44$6,464,744 · 2
R43$4,830,826 · 10
N01$1,832,551 · 1
R41$1,126,097 · 3

Investigators at Biomedical Research Models, Inc.

Investigator-initiatedAll funding

InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).

Rising Stars

First grant in the last 5 yrs

Not enough data

Emerging Leaders

6–10 yrs in

Not enough data

All-Time

Most funded here, all years

1Kejian Yang$6,904,4094 gr2Rebecca S Tirabassi$1,583,1032 gr3Dennis L. Guberski$1,564,5103 gr4Thomas R. Coleman$809,4112 gr5Barbara Whalen$747,2732 gr6Tiangen Wu$393,5891 gr7Edward Henry Kislauskis$346,2892 gr8Christian Grant$73,0841 gr

Largest grants

Testing for Preclinical efficacy in prevention or reversal of Type 1 Diabetes (T1$1,047,335
N01 · FY2009 · DK
Advancing a Mucosal HSV-2 Vaccine Towards Clinical Trials$1,000,000
R44 · FY2016 · AI
Advancing a Mucosal HSV-2 Vaccine Towards Clinical Trials$999,834
R44 · FY2014 · AI
Advancing a Mucosal HSV-2 Vaccine Towards Clinical Trials$999,334
R44 · FY2015 · AI
A Mucosal Vaccine for HSV-2$908,733
R44 · FY2010 · AI
A Mucosal Vaccine for HSV-2$891,829
R44 · FY2009 · AI
Testing for Preclinical efficacy in prevention or reversal of Type 1 Diabetes (T1$785,216
N01 · FY2011 · DK
A Mucosal Vaccine for HSV-2$762,971
R44 · FY2011 · AI
Neurogenic Compounds for Treating Diabetic Complications$500,000
R43 · FY2005 · DK
Neurogenic Compounds for Treating Diabetic Complications$500,000
R43 · FY2004 · DK
THE BBZDR RAT, NEW MODEL OF OBESITY/TYPE 2 DIABETES$452,092
R44 · FY2001 · DK
THE BBZDR RAT, NEW MODEL OF OBESITY/TYPE 2 DIABETES$449,951
R44 · FY2002 · DK
Developing small molecule therapeutics for lupus$434,829
R41 · FY2011 · AR
New Model For Virus Induced Autoimmunity$319,761
R41 · FY2004 · RR
Developing Small MIF Inhibitors for Rheumatoid Arthritis$306,263
R43 · FY2012 · AR
New Rat Model For Autoimmune Therapy Safety/Efficacy$300,694
R43 · FY2011 · DK
A Mucosal RSV Vaccine$300,000
R43 · FY2013 · AI
A Mucosal RSV Vaccine$300,000
R43 · FY2012 · AI
Selection of a device for intranasal administration of a mucosal vaccine for HSV-2$300,000
R43 · FY2017 · AI
A Mucosal Vaccine for HSV-2$295,807
R43 · FY2006 · AI